Free tool · No signup

Kidney disease treatment & trial finder

Choose your kidney diagnosis to see recently approved treatments and actively enrolling clinical trials for that condition — with plain-language evidence and links to ClinicalTrials.gov.

For information only — not medical advice. Always talk to your nephrologist.

Kidney treatment is advancing fast

17 FDA-approved therapies since 2018 8 in the last two years — plus 3 trials enrolling now.

17
Approved therapies
3
Trials enrolling
9
Conditions covered
1
1
5
1
1
6
2
18
19
20
21
22
23
24
25
26

New U.S. FDA approvals for a kidney indication, by year — across IgA nephropathy, lupus nephritis, C3 glomerulopathy, FSGS, diabetic and polycystic kidney disease, and more. Sources on each treatment card below. Verified July 2026.

Type
Common conditions

Treatment Options for Your Diagnosis

3

Foundational care

Start here

First-line care is blood-sugar control plus an ACE inhibitor or ARB and an SGLT2 inhibitor, often with a finerenone-type medicine added. Your nephrologist and diabetes team usually start here.

These are newer and recently approved therapies for Diabetic kidney disease (diabetic nephropathy) — not the full standard of care. Ask your care team whether any fit your situation.

B
Bayer
Finerenone (Kerendia)
FDA approved

Non-steroidal mineralocorticoid receptor antagonist

FIDELIO-DKD

Evidence: 18% lower risk of CKD progression and a 31% drop in albuminuria vs placebo.

View the FIDELIO-DKD study on ClinicalTrials.gov

Source: FDA prescribing information; FIDELIO-DKD, NEJM 2020Verified 2026-07-18

N
Novo Nordisk
Semaglutide (Ozempic)
FDA approved

GLP-1 receptor agonist

FLOW

Evidence: 24% lower risk of major kidney disease events vs placebo; trial stopped early for efficacy.

View the FLOW study on ClinicalTrials.gov

Source: FDA prescribing information; FLOW, NEJM 2024Verified 2026-07-18

A
AstraZeneca
Dapagliflozin (Farxiga)
FDA approved

SGLT2 inhibitor

DAPA-CKD

Evidence: 39% lower risk of kidney failure or death vs placebo across diabetic and non-diabetic CKD.

View the DAPA-CKD study on ClinicalTrials.gov

Source: FDA prescribing information; DAPA-CKD, NEJM 2020Verified 2026-07-18

Clinical Trials Related to Your Diagnosis

Actively enrolling studies related to Diabetic kidney disease (diabetic nephropathy). Whether a trial is right for you — and whether you qualify — is decided by the study team together with your nephrologist.

No actively enrolling trials we're tracking for Diabetic kidney disease (diabetic nephropathy) right now.

Browse all recruiting Diabetic kidney disease (diabetic nephropathy) trials on ClinicalTrials.gov

For information only — this is not medical advice, and nothing here is a recommendation to start, stop, or switch treatment. Every treatment decision should go through your nephrologist.

Manage your whole kidney journey

Lutango helps you track labs, meals, fluids, blood pressure, medications, and more — built specifically for chronic kidney disease.

Get started free